Other

Warner-lambert Company

Tillotts Pharma Ag

Chrysalis Pharma Ag

National Starch and Chemical Investment Holding Corporation

Chysalis Pharma Ag

Jean-Pierre Sachetto

Thomas Buser

Roly Bufton

Robert F Stepto

David J Lentz

Stephen Rimsa

Paul Tatarka

Markus Thoma

Jakob Silbiger

Olivier Mauzac

William Jeffery Sandborn

William John Tremaine

Heinz Zeller

Johannes Rehm

Gustav Lay

Gerd Borchers

Ingo Dake

Gary Loomis

Albrecht Dinkelaker

Richard Zdrahala

A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.

Type A gelatin capsule containing PUFA in free acid form

A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.

Type a gelatin capsule containing PUFA in free acid form

A polysaccharide selected from xanthan gum and HPMC is used for the treatment or prophylaxis of IBD, especially Crohn's Disease, left-sided ulcerative colitis or pouchitis.

Pharmaceutical composition for the treatment of inflammatory bowel disease

An aqueous foamable composition is provided having a delayed foaming action on expulsion from a pressurized container. The composition comprises a major amount of water, a water-immiscible liquified gas foaming agent, at least one foam-stabilizing and emulsifying surfactant, and a water-soluble polymer. The composition is particularly useful for rectal or vaginal administration of pharmaceuticals.

Aqueous foamable composition

Esterified starch composition

A thermoplastic polymer composition comprising: (a) a destructurized starch, and either (b) an effective amount of at least one compound selected from the following: (1) a polymer which contains at least two different types of functional groups, one of said types of these groups being hydroxyl groups; (2) at least one polymer which does not contain hydroxyl groups and is selected from the group consisting of polymers which contain at least two types of functional groups bound to the same molecule one type of these groups being carboxylate groups; (3) at least one polymer selected from the group consisting of polymers which contain tertiary amino groups and/or salts thereof and/or quaternary ammonium groups; (4) at least one polymer selected from the group of polysaccharides which have been chemically modified to contain added hydroxyalkyl groups and/or contain alkyl ether groups, and/or contain ester groups; (5) at least one compound selected from the group consisting of copolymers of vinyl pyrrolidone; (6) at least one compound selected from the group consisting of cationically modified polysaccharides; (7) at least one compound selected from the group consisting of anionically modified polysaccharides; (8) at least one polymer selected from the group of copolymers containing vinyl alcohol units together with aliphatic chain units as are obtained by copolymerization of vinyl esters, preferably vinyl acetate, with unsaturated monomers containing no functional group with subsequent hydrolysis of the vinyl ester group; (9) at least one compound selected from the group consisting of polysaccharide graft copolymers and graft copolymers of polysaccharide derivatives; (10) at least one compound selected from the group consisting of polyalkyleneimine polymers and polyalkyleneimine copolymers; (11) at least one compound selected from the group consisting of styrene sulfonic acid polymers, styrene sulfonic acid copolymers, and salts thereof; and (12) at least one compound selected from the group consisting of polymers and copolymers which contain carboxylic groups which partially or wholly are present in the form of their salts and wherein said polymers or copolymers do not contain further functional groups; or (c) At least one substantially water-insoluble thermoplastic polymer. combinations of (a), (b) and (c) are also disclosed.

Polymer compositions containing destructurized starch

The invention refers to a process for obtaining a melt of destruction starch containing a finite amount of electrolytes comprising:

Destructurized starch essentially containing no bridged phosphate groups

Growing community of inventors

Arlesheim, Switzerland

Jean-Pierre Sachetto